News

Bausch + Lomb Launches New Website to Help People Living With AMD

New Website offers Patients Comprehensive, Educational Resources to Navigate Life with Age-Related Macular Degeneration Bausch + Lomb, a leading global eye health company, has  announced the launch of SightMatters.com, a new educational online resource for people living with age-related macular degeneration (AMD). Bausch + Lomb launched the site to coincide with the start of AMD [Read More]

Study Finds That Anti-VEGF Drug Treatments For Wet AMD Do Not Cause Strokes

Three anti-VEGF drugs are in clinical use for treatment of wet age-related macular degeneration (wAMD). These are Lucentis (ranibizumab), off-label Avastin (bevacizumab), and Eylea (ranibizumab). The rate of stroke from intravitreal injections of Lucentis was found in the early clinical trials to be 0.2% (1 of 525) in the combined group of patients compared to [Read More]

Yet Another Sustained-Delivery Anti-VEGF Drug Ready For Phase 2

A report at the Hawaiian Eye & Retina 2019 conference revealed another sustained-delivery drug, GB-102, for treatment of wet age-related macular degeneration (AMD).  Graybug Vision’s ADAGIO study has now provided evidence that GB-102 can continuously inhibit activity of VEGF for several months. The treatment was well-tolerated in the study and found to be free of dose [Read More]

NIH researchers prevent blindness in animal models of dry AMD

Findings set stage for first clinical trial of stem cell-based therapeutic approach for AMD. Using a novel patient-specific stem cell-based therapy, researchers at the National Eye Institute (NEI) prevented blindness in animal models of geographic atrophy, the advanced “dry” form of age-related macular degeneration (AMD). The protocols established by the animal study* set the stage [Read More]